← All tasks
Task H-003 · Type H — Insufficient evidence (should abstain)
What clinical trial evidence exists for migalastat as a pharmacological chaperone therapy for Fabry disease?
Difficulty
medium
Rarity stratum
high
Evidence type
insufficient_evidence
MONDO ID
MONDO:0010526
Curator notes
VERIFIED by full-text grep (2026-09-07): "migalastat" does not appear in the 24 Fabry disease documents in this corpus version, which are cardiology-skewed (see A-004's ambiguity note).
Generation outcome
Abstained
No
Abstention correct
No
Gold in retrieved
n/a (no gold docs)
Generation cost
$0.000360
Claims
2
Supported
2
Contradicted
0
Unverifiable
0
Gold documents (0)
No gold documents — this is an insufficient-evidence (Type H) task; the correct answer is abstention.
Retrieved documents (6)
- Treatment of Anderson-Fabry Disease.pubmed:32183665
- Nucleoside-Modified mRNA Encoding Alpha-Galactosidase A Ameliorates Fabry Disease Phenotypes in Human IPSC-Derived Cardiomyocytes.pubmed:42591063
- Fabry disease cardiomyopathy: A state-of-the-art review.pubmed:40840785
- [Fabry disease].pubmed:28104284
- Fabry disease.pubmed:23931807
- Overcoming Resistance in Anderson-Fabry Disease: Current Therapeutic Challenges and Future Perspectives.pubmed:39685654
Generated claims (2)
supportedconfidence 0.90
Migalastat is described as an oral pharmacological chaperone therapy for Fabry disease.
pubmed:32183665
supportedconfidence 0.80
Pharmacological chaperone therapy, such as migalastat, is noted as an alternative to enzyme replacement therapy (ERT) for certain patients with Fabry disease.
pubmed:39685654